193 related articles for article (PubMed ID: 6177248)
1. Use of monoclonal antibodies in detection of melanoma-associated antigens in intact human tumors.
Thompson JJ; Herlyn MF; Elder DE; Clark WH; Steplewski Z; Koprowski H
Am J Pathol; 1982 Jun; 107(3):357-61. PubMed ID: 6177248
[TBL] [Abstract][Full Text] [Related]
2. Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.
Imam A; Mitchell MS; Modlin RL; Taylor CR; Kempf RA; Kan-Mitchell J
J Invest Dermatol; 1986 Feb; 86(2):145-8. PubMed ID: 3528308
[TBL] [Abstract][Full Text] [Related]
3. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
4. Expression of DR antigens in freshly frozen human tumors.
Thompson JJ; Herlyn MF; Elder DE; Clark WH; Steplewski Z; Koprowski H
Hybridoma; 1982; 1(2):161-8. PubMed ID: 6208123
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies selected to discriminate between malignant melanomas and nevocellular nevi.
Ruiter DJ; Dingjan GM; Steijlen PM; van Beveren-Hooyer M; de Graaff-Reitsma C; Bergman W; van Muijen GN; Warnaar SO
J Invest Dermatol; 1985 Jul; 85(1):4-8. PubMed ID: 3891875
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of human monoclonal antibody (2-139-1) in cutaneous melanocytic neoplasms in fixed tissue sections.
White WL; Tam ST; Mitchell MS; Yu MC; Kan-Mitchell J
J Histochem Cytochem; 1991 Jun; 39(6):777-85. PubMed ID: 1709658
[TBL] [Abstract][Full Text] [Related]
7. Antigen expression in canine tissues, recognized by a monoclonal antibody generated against canine melanoma cells.
Oliver JL; Wolfe LG
Am J Vet Res; 1992 Jan; 53(1):123-8. PubMed ID: 1539903
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies to human melanoma associated antigens: study of their specificity and visualization at the cellular level of the antigenic distribution.
Libert A; Ghanem G; Arnould R; Vercammen-Grandjean A; Carrel S; Lejeune F
Anticancer Res; 1983; 3(4):219-25. PubMed ID: 6576727
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.
Rudolph P; Lappe T; Schubert C; Schmidt D; Parwaresch RM; Christophers E
Am J Pathol; 1995 Dec; 147(6):1615-25. PubMed ID: 7495287
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical demonstration of S-100 protein and melanoma-associated antigens in melanocytic nevi.
Paul E; Cochran AJ; Wen DR
J Cutan Pathol; 1988 Jun; 15(3):161-5. PubMed ID: 2456315
[TBL] [Abstract][Full Text] [Related]
11. Immunoperoxidase staining for Ia-like antigens in paraffin-embedded tissues from human melanoma and lung carcinoma.
Wilson BS; Herzig MA; Lloyd RV
Am J Pathol; 1984 Apr; 115(1):102-8. PubMed ID: 6369992
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of antigen in human primary and metastatic melanomas by the monoclonal antibody 140.240 and its possible prognostic significance.
Natali PG; Roberts JT; Difilippo F; Bigotti A; Dent PB; Ferrone S; Liao SK
Cancer; 1987 Jan; 59(1):55-63. PubMed ID: 3539308
[TBL] [Abstract][Full Text] [Related]
13. The differential reactivity of benign and malignant nevomelanocytic lesions with mouse monoclonal antibody TNKH1.
Nakanishi T; Hashimoto K
Cancer; 1987 Apr; 59(7):1340-4. PubMed ID: 3545436
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes.
Gown AM; Vogel AM; Hoak D; Gough F; McNutt MA
Am J Pathol; 1986 May; 123(2):195-203. PubMed ID: 3518473
[TBL] [Abstract][Full Text] [Related]
15. Development of MoAb HMSA-2 for melanosomes of human melanoma and its application to immunohistopathologic diagnosis of neoplastic melanocytes.
Maeda K; Jimbow K
Cancer; 1987 Feb; 59(3):415-23. PubMed ID: 3539311
[TBL] [Abstract][Full Text] [Related]
16. The differential reactivity of cells of the melanocytic lineage with four monoclonal antibodies against IFN-gamma inducible molecules.
Vacca A; Frassanito A; Rimoldi D; Dammacco F; Carrel S
Anticancer Res; 1992; 12(1):1-9. PubMed ID: 1348919
[TBL] [Abstract][Full Text] [Related]
17. Use of NK1 C3 monoclonal antibody in the assessment of benign and malignant melanocytic lesions.
Mackie RM; Campbell I; Turbitt ML
J Clin Pathol; 1984 Apr; 37(4):367-72. PubMed ID: 6200506
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody to a highly glycosylated protein reacts in fixed tissue with melanoma and other tumors.
Atkinson B; Ernst CS; Ghrist BF; Ross AH; Clark WH; Herlyn M; Herlyn D; Maul G; Steplewski Z; Koprowski H
Hybridoma; 1985; 4(3):243-55. PubMed ID: 4043988
[TBL] [Abstract][Full Text] [Related]
19. Fluctuations in the expression of a glycolipid antigen associated with differentiation of melanoma cells monitored by a monoclonal antibody, Leo Mel 3.
Werkmeister JA; Triglia T; Mackay IR; Dowling JP; Varigos GA; Morstyn G; Burns GF
Cancer Res; 1987 Jan; 47(1):225-30. PubMed ID: 3791209
[TBL] [Abstract][Full Text] [Related]
20. Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma and nevi.
Kornstein MJ; Brooks JS; Elder DE
Cancer Res; 1983 Jun; 43(6):2749-53. PubMed ID: 6342758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
